In this article such is said if I interpret it correctly.

BCL6 contributes to resistance against Gleevec.

An experimental drug RI-BPI is being tested.

http://medicalxpress.com/news/2011-05-drug-aggressive-childhood-leukemia.html

Similar:

http://medicalxpress.com/news/2011-05-key-drug-resistant-leukemia.html

http://www.the-scientist.com/?articles.view/articleNo/29707

More links:

http://www.augos.com/temp/Temp-BCL6-Leukemia.html

http://www.augos.com/diverses/Krebs-Kindheitsleukaemie.html

http://www.augos.com/diverses/Krebs-ALL.html

Regards,

Joachim (not a medic)

That is what I thought as well; but then it turns out that not a single pediatric leukemia case was studied in that study. Read the paper press releases and asked the corresponding author. Apparently the findings related to adult CML. In any event, we are about to report our finding of BCL6 deficiency in childhood leukemia. So I was curious if there were other studies out there I am not aware of.

Certainly, Ph+ ALL in adults is biologically different from Ph+ALL in children. Thus, we should wait for your data. I am not aware of any other studies in childhood ALL. However, such studies can be expected, given the frequent involvement of BCL6 in B cell neoplasm. Good luck!

Thanks. The paper I believe was on CML rather than Ph+ ALL with BCR-ABL (190). FYI, we also checked adult Ph+ ALL cases. ALL-1 cell line for example has a frame shifting mutation generating a small (~17 kDa) truncated protein. Our study involved more than 50 primary ALL cases and we have been able to detect low levels of intact BCL6 only in two cases. siRNA depletion of BCL6 in Ph+ ALL cells did not affect their viability. If you have access to a large number of adult Ph+ cases, I would love to collaborate with you to look at their BCL6 expression levels. That would make our study certainly more complete. Our plan is to submit it to Nature or NEJM.

Unfortunately not, since I am a ped onc. For such pediatric patients you should contact Martin Schrappe in Kiel, Germany who is the chair of the BFM group, including a prospective protocol on Ph+ ALL in children. Good luck with your work and the submission.

Okay, thanks. Mit freundlichen Gruessen !